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Abstract
The serine/threonine kinase, Pim-1, appears to be involved in regulating proliferation, differentiation and cell survival of lymphoid and
myeloid cells. In this study, we have found that amino acid residues 140–147 (RKRRQTSM) at the C-terminal end of p21Cip1/WAF1, a cyclin-
dependent kinase (CDK) inhibitor, constitute an ideal phosphorylation consensus sequence for Pim-1. We demonstrate that Pim-1 efficiently
phosphorylates this peptide sequence as well as the p21 protein in vitro. We also demonstrate by pull-down assay and by immunoprecipitation
that Pim-1 associates with p21. During phorbol ester-induced differentiation of U937 cells, both Pim-1 and p21 expression levels increase with
Pim-1 levels increasing in both the nucleus and cytoplasm while p21 remains primarily cytoplasmic. Co-transfection of wild type p21 with
wild type Pim-1 results in cytoplasmic localization of p21 while co-transfection of wild type p21 with kinase dead Pim-1 results in nuclear
localization of p21. Consistent with the results from the phosphoamino acid assay, Pim-1 phosphorylates transfected p21 only on Thr145 in
p21-deficient human fibroblasts and this phosphorylation event results in the cytoplasmic localization of p21. These findings demonstrate that
Pim-1 associates with and phosphorylates p21 in vivo, which influences the subcellular localization of p21.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Cell cycle progression results from the coordinated ex-
pression and interaction of positive regulatory proteins,
including cyclins and their associated cyclin-dependent kina-
ses (CDK), and negative regulatory proteins, CDK inhibitors
[1]. The first identified and most extensively studied CDK
inhibitor is p21Cip1/WAF1 (hereafter referred to as p21). p21 is
known to directly inhibit kinase activities of a wide range of
cyclin/CDK complexes, resulting in a general arrest of the
cell cycle [2,3]. It also binds to the proliferating cell nuclear
antigen (PCNA), a subunit of DNA polymerase y, which
leads to inhibition of DNA replication directly without af-
fecting DNA repair [4,5]. Besides functioning in cell cycle
arrest and DNA synthesis control, p21 has also been shown
to be involved in many processes including differentiation,
stress response, apoptosis, development and tumorigenesis
(reviewed in Refs. [6–8]). Consistent with its numerous
cellular functions, p21 has been found to participate in a
number of specific protein–protein interactions. In addition
to associating with cyclin CDKs and PCNA [2–4], p21 has
also been reported to bind to transcription factors (c-Myc
[9], E2F [10], C/EBP-a [11], STAT3 [12]), proteins involved
in apoptosis (procaspase 3 [13], stress associated protein ki-
nase (SAPK) [14], apoptosis signal regulating kinase (ASK1)
[15]) and other proteins (SET [16], calmodulin [17], HPV-16
E7 [18], GADD45 [19], TOK-1 [20], and protein kinase CK 2
[21]).
The proto-oncogene Pim-1 was originally identified as a
preferential integration site of Moloney murine leukemia
virus, which induces T-lymphomas in mice [22]. Oncoge-
nicity of Pim-1 has been well documented in both transgenic
and retroviral models [23,24]. By itself, Pim-1 has low
oncogenic potential but cooperates strongly with c-Myc, L-
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Myc, N-Myc, Bcl-2 and Gfi-1 in T-cell lymphomagenesis
[25–28]. Besides functioning in lymphomagenesis, Pim-1
has also been shown to be involved in the IL-3 signal
transduction pathway, in cell cycle regulation and prolifer-
ation, in apoptosis and cell survival (reviewed in Ref. [29])
[30].
Pim-1 is a highly conserved serine/threonine kinase and its
preferential phosphorylation consensus sequence was dem-
onstrated to be (Arg/Lys)4-X-Ser/Thr-XV, where XVis likely to
be neither a basic nor a large hydrophobic residue [31,32]
Currently, eight proteins have been reported to be phosphory-
lated by Pim-1. These are p100 (a transcriptional co-activator
of c-Myb) [33], cdc25A phosphatase (a cell cycle phospha-
tase) [34], HP1 (heterochromatin protein 1, a transcriptional
repressor) [35], PAP1 (Pim-1 associated protein 1, whose
function is unknown) [36], PTP-U2S (a tyrosine phospha-
tase) [37],NFATc1 (a transcription factor) [38], TFAF2/SNX6
[39] and nuclear mitotic apparatus protein (NuMA) [40].
Because Pim-1 is involved in multiple cellular activities, it is
very likely that Pim-1 has more substrates than presently
identified.
Because p21 has a potential Pim-1 phosphorylation site
located in the C-terminal end of p21, we were interested to
determine if p21 might also be a substrate for Pim-1. In this
study, we have identified p21 as a Pim-1-associating protein
in vivo and have demonstrated that p21 protein is phosphory-
lated by Pim-1 specifically on Thr145.We also demonstrate by
co-transfection of p21 null cells that wild type Pim-1 causes a
translocation of p21 to the cytoplasm whereas p21 remains
nuclear in the presence of the kinase dead Pim-1.
2. Materials and methods
2.1. Cell culture and differentiation induction
Human monoblastoid leukemia U937 cells (ATCC CRL-
1593.2) were grown in RPMI 1640 media (Gibco, Grand
Island, NY) plus 10% FBS. The p21 null human fibroblast
cells were cultured as previously described [41]. Phorbol
ester (PMA), 10 ng/ml culture was used to induce U937 cell
differentiation during a 48 h period.
2.2. Plasmids and transfections
The cDNA for human p21 (provided by Dr. Bert Vogel-
stein, The Johns Hopkins University School of Medicine
and The Howard Hughes Medical Institute) was subcloned
into the expression vector pBK/CMV (Stratagene, La Jolla,
CA). To replace the Thr145 with Asp or Ala, a PCR-based
site-directed mutagenesis kit (Stratagene) was used. The
primer for T145D was CCAGGACAGCATGACA-
GATTTCTACCACTCCAAAC and the primer for T145A
was CAAGCTTCCATGACAGATTTCTACCACTCC-
CAAAC. Transfection of p21 null fibroblasts was carried
out using lipofectamine 2000 (Invitrogen, Carlsbad, CA).
2.3. In vitro kinase assay
Kemptide peptide LRRASLGwas purchased from Sigma.
The p21 peptide RKRRQTSM, the p21 reverse peptide MST
QRRKR, the modified p21 peptides RKRRQTAM and RKR
RQASM, the cdc25A peptide KRRKSM and the histone H1
peptide KRRASGP were synthesized on campus. Kinase
assays were performed as previously described [42]. Phos-
phorylation was quantitated on a Packard 1900 TR liquid
scintillation analyzer.
2.4. Protein extraction and Western blot analysis
At different times after the addition of PMA, U937 cells
were lysed by suspension in RIPA lysis buffer (50 mM Tris
pH 8.0, 150 mM NaCl, 1% NP40, 14 mM 2-mercapto-
ethanol, and 2 mM EDTA) followed by gentle sonication.
The proteins (40 Ag) were separated on 12% SDS poly-
acrylamide gel by electrophoresis and were transferred onto
PVDF membrane (Fisher Scientific, Pittsburgh, PA). For
Pim-1 analysis, the membranes were then blocked in PBS/
Tween (PBS with 5% non-fat powered milk and 0.05%
Tween 20) at room temperature for 2 h. The blot was then
incubated with affinity-purified rabbit anti-Pim-1 at 1:100 in
PBS/Tween for 1 h. The membranes were washed with
PBS/Tween for 5, 10 and 15 min and incubated with
horseradish peroxidase conjugated goat anti-rabbit antibody
diluted 1:20,000 (Pierce, Rockford, IL) for 1 h at room
temperature. After repeating the washing steps, the signal
was detected by chemiluminescence using the Pierce Super
Signal West Pico System (Pierce). Membranes were stripped
for reprobing by incubating in stripping buffer (2% SDS,
62.4 mM Tris–HCl pH 6.8, 100 mM 2-mercaptoethanol) for
30 min at 50 jC. The membranes were then reblocked and
probed for p21 or actin. Anti-p21 antibody (C-19) and anti-
actin antibody were purchased from Santa Cruz Biotech
(Santa Cruz, CA).
Nuclear and cytoplasmic fractionation was carried out as
previously described [43]. During differentiation at selected
time points, 400 Al cytoplasmic extract and 400 Al nuclear
extract were made from 107 U937 cells. Equal volumes of
protein (30 Al) from cytoplasmic or nuclear fractions were
separated on 12% SDS-PAGE and subjected to Western blot
with anti-Pim-1 antibody or anti-p21 antibody.
2.5. Phosphorylation of immunoprecipitated p21 and
phosphoamino acid analysis
Cellular extracts were prepared as described above. Pro-
teins (500 Ag) were gently rotated with 1 Ag of anti-p21
antibody and 15 Al of protein G agarose (Boehringer Man-
nheim, Germany) at 4 jC for 1 h. The immunocomplex was
washed five times with RIPA buffer and then used in a kinase
assay as previously described [42]. In the peptide competi-
tion assay, 1 Al of 10 mM p21 peptide or p21 reverse peptide
was included in the reaction. After 30 min, the reaction
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mixture was boiled in Laemmli sample buffer and phos-
phorylated proteins were separated on a 10% SDS polyacry-
lamide gel. The resulting gel was visualized by autoradio-
graphy.
For phosphoamino acid analysis, phosphorylated p21 and
Pim-1 were separated by SDS-PAGE and transferred to a
PVDF membrane. The portion containing phosphorylated
p21 was excised after autoradiography and the membrane
was washed five times with deionized water. One-dimen-
sional and two-dimensional thin layer chromatography
(TLC) analyses were performed according to the method
described previously [44,45].
2.6. In vitro ‘‘pull-down’’ assay
GST-Pim-1 and GST were generated as previously des-
cribed [31]. Two micrograms of the purified GST-Pim-1 or
GST was first applied to Glutathione Sepharose 4B beads
(Pharmacia, Uppsala, Sweden) in RIPA buffer. After exten-
sive washing of the glutathione sepharose 4B/GST-Pim-1 or
GST complex, 200 Ag of U937 cell lysates were added and
incubated with the complex for 1 h at 4 jC. With the peptide
competition, increasing amounts of 10 mM p21 peptide (1,
5 or 10 Al) or 10 Al of 10 mM p21 reverse peptide was
added to the reaction mixture, respectively. The complexes
were extensively washed with RIPA lysis buffer and then
suspended in Laemmli buffer, boiled for 5 min, and sepa-
rated on 12% PAGE. p21 and GST-Pim-1 proteins were de-
tected by Western blot analysis as described above.
2.7. Immunoprecipitation assay
U937 cell lysates (500 Ag) were gently mixed with 1 Ag
anti-Pim-1 antibody and protein G-agarose (Boehringer
Mannheim) for 1 h at 4 jC and washed with RIPA buffer
five times. The bound proteins were separated by 12% SDS-
PAGE, blotted onto a PVDF membrane and reacted with
anti-Pim-1 antibody or with C-19 anti-p21 antibody.
2.8. Indirect immunofluorescence
Following two washes in 1 PBS, the U937 cells were
fixed in 80% methanol for 20 min. Nonspecific antibody
binding was blocked by incubation with 3% bovine serum
albumin (BSA) in 1 PBS for 1 h at 4 jC followed by a 1
h incubation with specific antibodies diluted 1:50 in 1.5%
BSA. A polyclonal rabbit Pim-1 peptide antibody (Stress-
Gen, Vancouver, Canada), raised against the N-terminal
peptide sequence of residues 1-37 of Pim-1, was used to
localize Pim-1 protein. To localize p21 in the two cell types,
a monoclonal mouse IgG, WAF-1(Ab-1) was used (Onco-
gene, Cambridge, MA). The unbound antibodies were
removed by three 5-min washes in 1.5% BSA. Goat anti-
rabbit IgG antibody conjugated to fluorescein isothiocyanate
(FITC; Cappel Scientific Division, Malvern, PA) was
diluted 1:50 in 1.5% BSA and applied to the coverslips
for 1 h as a secondary antibody to Pim-1. Donkey anti-
mouse IgG antibody conjugated to Cyk5 (Jackson Labo-
ratories, Bar Harber, ME) was used in a 1:50 dilution in
1.5% BSA to localize p21. Unbound conjugated antibody
was removed with three washes in 1.5% BSA and one wash
in 1 PBS. Coverslips were mounted on microscope slides
(Fisher Scientific) using the mounting medium Vectashield
(Vector Laboratories, Burlingame, CA) that contained pro-
pidium iodide. Detection and imaging was achieved using a
Bio-Rad 1024 laser confocal microscope (Bio-Rad Labora-
tories, Hercules, CA). The specific wavelengths for fluo-
rescent visualization were 522 nm for FITC, 598 nm for
propidium iodide and 750 nm for Cyk5 and the three
images were merged by computational manipulation. Pre-
immune serum was used as a negative control for Pim-1 and
antibody specificity was verified by a competition assay
(data not shown). For staining p21 in p21 null fibroblasts, a
mouse monoclonal antibody against human p21 (1:100,
Santa Cruz) was used. The second antibody was goat anti-
mouse IgG conjugated to Oregon green (1:400, Molecular
Probes).
3. Results
3.1. Pim-1 kinase phosphorylates a peptide derived from the
C-terminal end of p21 protein
The C-terminal end of p21 protein contains the sequence
RKRRQTSM (amino acid residues 140–147) that is a
preferred phosphorylation sequence for Pim-1 [2,3,32,42].
By using the GST fusion protein with either wild type or
kinase dead (mutated ATP binding site) Pim-1, we found
that only GST-Pim-1 (wild type), but not the GST-Pim-1
(kinase dead) or GST alone, could phosphorylate the C-
terminal peptide of p21 (Fig. 1A). However, the GST-Pim-1
(wild type) did not phosphorylate the p21 reverse peptide
(MSTQRRKR) (Fig. 1B). We further evaluated the phos-
phorylation of p21 peptide by comparing its phosphoryla-
tion with that of peptides previously used to evaluate Pim-1
phosphorylation activity. As shown in Fig. 1B, p21 peptide
is highly phosphorylated by Pim-1 compared to the other
substrates previously shown to be phosphorylated by Pim-1,
which includes H1 peptide, Kemptide and cdc25A peptide.
These results show that the p21 peptide is efficiently
phosphorylated by the wild type Pim-1, and p21 is a better
substrate than other peptide substrates reported previously.
3.2. Preferential phosphorylation of residue Thr145 of p21
protein
The C-terminal peptide of p21 (RKRRQTSM) contains
two potential Pim-1 phosphorylation sites next to one
another, Thr145 and Ser146. Thr145 has been shown to be
phosphorylated by PKA and Akt while Ser146 has been
shown to be phosphorylated by PKC [46,47]. Phosphor-
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ylation of either residues would appear to be important in
regulating p21 associating with PCNA and also possibly its
nuclear localization based on the nuclear localization signal
at residues 140–153, which includes both Thr145 and Ser146
[8,48]. Therefore, it was of interest to determine if one or the
other of the residues would be preferentially phosphorylated
by Pim-1 kinase. Two modified p21 peptides (RKRRQTAM
and RKRRQASM) with either the Thr145 or Ser146 changed
to alanine were synthesized. Phosphorylation of the p21
peptide and the modified p21 peptides were conducted to
evaluate the efficiency of phosphorylation by Pim-1 kinase
at residues Thr145 and Ser146. The phosphorylation of the
three different p21 peptides showed that peptides with Thr145
were readily phosphorylated as compared to the peptide with
only Ser146 (Fig. 1C). In addition, the amount of 32P
incorporation is almost identical for both the p21 peptide
(RKRRQTSM) and the modified p21 peptide (RKRRQ
TAM), while the amount of 32P incorporation in p21 peptide
(RKRRQASM) was extremely low. These results suggested
that phosphorylation of p21 peptide by Pim-1 occurred only
on Thr145.
3.3. Phosphorylation of p21 protein by Pim-1 in vitro
In order to determine if Pim-1 kinase would phosphorylate
p21 protein in vitro, p21 protein was immunoprecipitated
from PMA-treated U937 cells and subjected to the kinase
assay (Fig. 2). We found that the p21 protein was phosphory-
lated by GST-Pim-1 but not by kinase dead GST-Pim-1 or by
GSTalone. When the p21 peptide was added as a competitive
inhibitor in the kinase reaction, the phosphorylation of the
p21 protein was greatly inhibited. However, when the same
amount of p21 ‘‘reverse’’ peptide was included in the
Fig. 2. In vitro phosphorylation of p21 protein by Pim-1 kinase. p21 protein
was immunoprecipitated from PMA-treated U937 cell lysates and used as
substrate in the Pim-1 kinase assay. GST-Pim-1 (wild type), GST-Pim-1
(kinase dead), and GSTwere expressed in Escherichia coli, purified for use
in the kinase assay. Phosphorylated proteins were separated by 12% SDS-
PAGE and visualized by autoradiography. p21 peptide and p21 reverse
peptide were put into the kinase assay as competitors with the p21 protein.
The lower panel shows Western blot (WB) for p21 used in the
phosphorylation reactions. Data are representative of three independent
experiments.
Fig. 1. Phosphorylation of p21 peptide by Pim-1 kinase. (A) Phosphor-
ylation of p21 peptide by GST-Pim-1-wt (wild type) but not by GST-Pim-1-
KD (kinase dead) or by GST. 32P incorporation is expressed as counts per
minute (cpm). (B) Comparison of the phosphorylation of different peptides
by Pim-1 kinase. (C) The kinetics of the phosphorylation of p21 peptide
(E) and the two modified p21 peptides (RKRRQTAM, 5; RKRRQASM,
.) by GST-Pim-1 (wild type). Each point is the mean of triplicate samples
and lines represent the calculated trend for the data.
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reaction, there was no effect on the phosphorylation of p21
protein. This result shows that Pim-1 kinase specifically
phosphorylates p21 protein in vitro.
3.4. Pim-1 phosphorylates p21 on Thr145
To provide further information about the specific site
being phosphorylated by Pim-1 in the p21 protein, a phos-
phoamino acid assay was carried out. p21 protein was
immunoprecipitated from U937 cells and subjected to the
kinase assay with Pim-1 kinase. Phosphorylated p21 proteins
were subjected to phosphoamino acid analysis. Both one-
and two-dimensional TLC were used to determine which
residues were being phosphorylated by Pim-1 [44,45]. We
found that p21 was only phosphorylated on threonines
providing further support for our hypothesis that the pref-
erential residue being phosphorylated by Pim-1 is Thr145
(Fig. 3).
3.5. Binding of p21 protein to Pim-1 in ‘‘pull-down’’ assays
In order to test whether p21 protein associates with Pim-1,
cell lysates from PMA-treated U937 cells were prepared and
incubated with GST-Pim-1 attached to glutathione-sepharose
4B beads. After the beads were washed, they were boiled in
sample buffer and the liberated proteins were separated by
SDS-PAGE and Western blotted with anti-p21 antibody. We
found that p21 protein specifically associated with the Pim-1
on the beads (Fig. 4, lane 1). When the p21 peptide was
added to the lysate–GST–Pim-1 bead mixture, the peptide
was able to compete for the binding to the Pim-1. With
increasing amounts of added p21 peptide, the amount of
associated p21 protein with Pim-1 beads decreased (Fig. 4,
lanes 2–4). However, the p21 reverse peptide was not
capable of competing with the p21 protein for binding to
GST-Pim-1 (Fig. 4, lane 5). No p21 protein was observed
with beads attached with only GST (data not shown). These
results demonstrate that Pim-1 specifically associates with
p21 protein in vitro.
3.6. Binding of p21 protein to Pim-1 in
immunoprecipitation assays
Interaction between p21 protein and Pim-1 was also
evaluated by immunoprecipitation assay. Cell lysates were
prepared from PMA-treated U937 cells and precipitated
with either anti-Pim-1 antibody or non-specific IgG. The
precipitates were then subjected to Western blot analysis
using either anti-p21 antibody or anti-Pim-1 antibody
(Fig. 5). p21 protein was detected in whole lysates and
only the precipitate with the anti-Pim-1 antibody but not
in the precipitate with IgG. These results indicate that
p21 protein associates with Pim-1 in vivo in U937 cells.
Fig. 3. Phosphoamino acid analysis of p21. p21 was immunoprecipitated
from U937 cell lysates, phosphorylated by Pim-1, separated by SDS-PAGE
and transferred to PVDF membrane. Phosphorylated p21 was excised and
hydrolyzed with HCl. The amino acid composition was determined by
either (A) one-dimensional TLC or (B) two-dimensional TLC. The dotted
circles indicate the position of the control phosphoamino acids.
Fig. 4. Association of p21 protein with Pim-1 kinase in a ‘‘pull-down’’
assay. p21 protein was isolated from PMA-treated U937 cell lysates on
GST-Pim-1 bound to glutathione sepharose 4B beads and subjected to
Western blot analysis with anti-p21 antibody. Lane 1 shows p21 protein
bound by the GST-Pim-1 beads. Lanes 2, 3 and 4 demonstrate successful
competition of p21 protein from binding to GST-Pim-1 beads by increasing
amount of p21 peptide. Lane 5 shows that the p21 reverse peptide is not
able to compete with p21 protein for binding to the GST-Pim-1 beads. The
lower panel shows the equal amount of GST-Pim-1 by Western blotting
with anti-Pim-1 antibody. This result is representative of three independent
experiments.
Fig. 5. Association of p21 protein with Pim-1 as determined by immu-
noprecipitation (IP). Cell lysates from PMA-treated U937 cells (48 h) were
immunoprecipitated with anti-Pim-1 antibody or non-specific IgG. Precip-
itates were separated by 12%SDS-PAGE and subjected toWestern blot (WB)
analysis with either anti-Pim-1 antibody or anti-p21 antibody. The positions
of the p21 and Pim-1 proteins are indicated by arrows. Similar results were
obtained in three other independent experiments.
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3.7. Kinetics of p21 and Pim-1 expression during U937 cell
differentiation
Because p21 was found to bind to Pim-1 and to be
phosphorylated by Pim-1, it was of interest to examine
the expression pattern of p21 and Pim-1 proteins simul-
taneously during U937 cell differentiation. After inducing
differentiation with PMA, both Pim-1 and p21 levels
increased gradually (Fig. 6). At 48 h post-stimulation, a
time point when monocytic differentiation was well
underway (Fig. 8), Pim-1 and p21 proteins were highly
expressed. As a control, we also demonstrated that there
was no change in the expression level of actin during
U937 cell differentiation.
3.8. Cellular localization of p21 and Pim-1 during the
course of U937 cell differentiation
Previous studies have shown that p21 is found pri-
marily in the nucleus of myeloid cells induced to differ-
entiate with vitamin D3, with translocation to the
cytoplasm later during the course of differentiation [15].
In order to determine if there was a correlation between
the localization of Pim-1 with that of p21 during PMA-
induced differentiation, the cytoplasm and nucleus of
U937 cells induced to differentiate with PMA were
analyzed separately using Western blot. As shown in
Fig. 7, the localization of Pim-1 proteins is seen primar-
ily in the nucleus early during differentiation (6–12 h)
and then appears to increase in both the cytoplasm and
the nucleus later in differentiation (24–48 h). Most of
p21 is found in the cytoplasm starting as early as 6 h
with levels increasing steadily to the 48 h time point.
However, the appearance of p21 is just barely detectable
in the nucleus at 6–12 h. Increases are seen primarily in
the cytoplasm from 12 to 48 h. These samples were also
evaluated by confocal microscopy confirming the Western
blot results. As can be seen in Fig. 8, the cellular
morphology indicates that the U937 cells are undergoing
differentiation at 24 h. This is clearly demonstrated in
column 3 by the change in nuclear shape from round (0 h) to
the classic kidney bean shape (48 h). Before treatment with
PMA, Pim-1 protein can be seen in both the cytoplasm and
nucleus (column 2). However, after 24 h exposure to
PMA, there is an increase of Pim-1 level in the nucleus.
By confocal microscopy, the level of Pim-1 in the
Fig. 6. Kinetics of p21 and Pim-1 expression during U937 cell
differentiation. Cell lysates from U937 cells were prepared at different
time points following PMA-induced differentiation. The proteins were
separated by 12% SDS-PAGE and subjected to Western blot analysis
sequentially with either anti-Pim-1, anti-p21 or anti-actin antibodies.
Similar results were obtained in two other independent experiments.
Fig. 7. Subcellular localization of p21 and Pim-1 during differentiation of
U937 cells. Nuclear (N) and cytoplasmic (C) fractionation of U937 cells
was prepared at different time points during PMA-induced differentiation.
Proteins from various fractions were separated by 12% SDS-PAGE and
subjected to Western blot analysis with both anti-p21 and anti-Pim-1
antibodies. These findings were confirmed in two other independent
experiments.
Fig. 8. (top) Distribution of Pim-1 and p21 proteins during U937 cell differentiation. U937 cells were induced to differentiate with 10 ng/ml of PMA. The cells
were stained respectively at 6, 24 and 48 h after the addition of PMA to study the distribution of Pim-1 and p21 by confocal laser scanning microscopy. Cells
not induced with PMA are controls (0 h) as shown in the top row. Column 1 (blue) represents cells stained for p21 (Cyk5). In Column 2, FITC (green) label
indicates Pim-1 distribution while in Column 3 the nuclei have been stained with propidium iodide (red). Column 4 results from the computational merging of
Pim-1 (green) and the nucleus (red) shown as a yellow color. Column 5 represents the merged images of Pim-1 (green) and p21 (blue) as shown by a light blue
color. The computational merging of all three labels is in column 6 showing the distribution of both proteins, Pim-1 and p21, within the nucleus and the
cytoplasm.
Fig. 9. (bottom) Pim-1 alters the cellular localization of p21. (A) Wild type (Wt) Pim-1 or kinase dead (KD) Pim-1 and p21 were co-transfected into p21 null
human fibroblasts at a ratio 10:1. The localization of p21 was visualized by immunostaining with anti-p21 antibody. When wild type Pim-1 was co-transfected
with p21, p21 was localized in the cytoplasm (top row). However, when kinase dead Pim-1 was co-transfected with p21, p21 was localized in the nucleus
(bottom row). (B) When p21 T145Awas transfected into p21 null human fibroblasts, the p21 was localized in the nucleus. When p21 T145D was transfected
into p21 null human fibroblasts, the p21 was localized in the cytoplasm. (C) When p21 T145D was co-transfected with wild type Pim-1 or kinase dead Pim-1,
p21 was localized in the cytoplasm. When p21 T145A was co-transfected with wild type Pim-1 or kinase dead Pim-1, p21 was localized in the nucleus.
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Fig. 9.
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cytoplasm is not as evident as detected by Western blot
(Fig. 7), and part of this observation may be due to the
apparent aggregation of Pim-1 as detected by confocal
microscopy at 48 h. In contrast, p21 appears to be
predominantly in the cytoplasm before PMA treatment
(column 1) and does not appear to change its overall
location after 24 h exposure to PMA. The general distri-
bution of Pim-1 and p21 protein is more evident when
one compares the merged images, columns 5 and 6. There-
fore, there is a difference in the induction of differentiation
by Vitamin D3 and PMA, in that with PMA very little
p21 is found in the nucleus at the early stage of differen-
tiation. However, the similarity between these inducers is
that p21 tends to be primarily cytoplasmic during differen-
tiation.
3.9. Pim-1 induces cytoplasmic localization of p21
Our observations that p21 associates with and is phos-
phorylated by Pim-1 encouraged us to determine the bio-
logical function of this phosphorylation event. Therefore,
p21 null fibroblasts were co-transfected with either wild
type p21 and wild type Pim-1 or with wild type p21 and
kinase dead Pim-1. The cellular localization of p21 in
transfected cells was determined by immunostaining with
anti-p21 antibody. As shown in Fig. 9A, the presence of
the wild type Pim-1 resulted in the distribution of p21
primarily in the cytoplasm. However, with the kinase
dead Pim-1, p21 was found almost exclusively in the
nucleus. This result demonstrates that in vivo phosphor-
ylation of p21 by Pim-1 results in the cytoplasmic local-
ization of p21 in a manner similar to that seen for Akt
[47].
3.10. Mutation of Thr145 of p21 to aspartic acid mimics
phosphorylation and influences its subcellular localization
To further demonstrate the effect of phosphorylation of
p21 on its cellular localization, we mutated Thr145 to either
alanine (to eliminate the Pim-1 phosphorylation site) or to
aspartic acid (to mimic the phosphorylated form of p21). By
transfection of either p21 T145A or p21 T145D into p21 null
fibroblasts, we were able to see that changing the charge on
the Thr145 of p21 was enough to influence its cellular local-
ization. As shown in Fig. 9B, when p21 T145Awas transfec-
ted into cells, p21 was found to be almost exclusively nuclear.
However, when p21 T145D was transfected into cells, p21
was found to be localized primarily in the cytoplasm.
3.11. Pim-1 phosphorylates p21 on Thr145 in vivo
To demonstrate that Pim-1 phosphorylation of p21 on
Thr145 determines the cellular localization of p21, p21
T145D and p21 T145A were co-transfected with wild
type Pim-1 or kinase dead Pim-1, respectively, into p21
null human fibroblasts. As shown in Fig. 9C, when p21
T145D was co-transfected with wild type Pim-1 or kinase
dead Pim-1, the p21 was localized predominantly in the
cytoplasm. However, when p21 T145A was co-transfected
with either wild type Pim-1 or kinase dead Pim-1, the
localization of p21 was found to be primarily in the
nucleus. This result indicates that Pim-1 phosphorylation
of p21 in vivo occurs only on residue Thr145, and not on
Ser146 because it was available for phosphorylation, and
that this phosphorylation event leads to cytoplasmic loca-
lization of p21.
4. Discussion
In this report, we describe experiments demonstrating that
Pim-1 directly binds to and phosphorylates the CDK inhibitor
p21 at Thr145. During PMA-induced differentiation of U937
cells, expression levels of Pim-1 kinase increase in both the
cytoplasm and nucleus, while p21 protein increases primarily
in the cytoplasm (Figs. 6 and 7). We observed that during the
early stage of differentiation (0–12 h), Pim-1 kinase was
localized primarily in nucleus, but p21 protein was found to
be cytoplasmic and almost undetectable in the nucleus. This
might be due to the nuclear p21 protein being phosphorylated
by Pim-1 kinase and then translocated to the cytoplasm as
was observed when Pim-1 and p21 were co-transfected into
p21-deficient human fibroblasts (Fig. 9). However, at the
later stage of U937 cell differentiation (24–48 h), a small
amount of p21was also detected in the nucleus although there
were high levels of nuclear Pim-1 kinase. This might be
explained by the fact that during induced differentiation of
myeloid cells, that the serine/threonine phosphatases, PP1
and PP2A, are up-regulated [49–51]. It is likely that these
phosphatases dephosphorylate p21 protein in the cytoplasm
allowing p21 to translocate back into the nucleus. Therefore,
the localization of p21 at any point during differentiation
would be determined by the balance of phosphatase and
kinase activities.
Phosphorylation of p21 by Pim-1 kinase has important
implications for the potential regulation of p21 function.
First, phosphorylation of p21 has been associated with the
growth arrest and differentiation of PC12 nerve cells [52].
Secondly, recent studies show that phosphorylation of p21
within residues 140–147 (RKRRQTSM), which also is the
preferred phosphorylation site of Pim-1, results in the
inhibition of p21–PCNA complex formation [46]. When
bound to PCNA, p21 is degraded more slowly compared
with p21 binding to cyclin/CDK, which increases the rate of
p21 degradation [53]. Thirdly, phosphorylation of p21
protein is also necessary for p21/procaspase 3 complex
formation that hinders Fas-mediated cell death [54]. Finally,
as mentioned in the introduction, p21 has more than 10
different binding partners. It is interesting that a single small
molecule can form high-affinity complexes with such a large
spectrum of different targets. However, it has been shown
that p21 is a very flexible protein with little or no secondary
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structure [55]. It is also possible that several kinases can
phosphorylate p21 at different sites and thereby further
modify its secondary structure to conform to the shape of
the target molecules. Besides Pim-1, three protein kinases,
PKC, PKA and Akt have been reported to phosphorylate
p21 [46,47] and all may have a significant impact on p21
function in vivo.
These three kinases, PKC, PKA and Akt, are constitu-
tively expressed but require some sort of post-translational
modification for activity via an activation signal initiated at
the surface of the cell. For example, PKC requires lipid
second messengers (diacylgycerol) and phosphorylation
(reviewed in Ref. [56]), PKA requires the second messenger,
cAMP and A-kinase anchor proteins (reviewed in Ref. [57])
and Akt requires the lipid phosphatidylinositiol 3,4,5-triphos-
phate and multiple phosphorylations from an upstream kin-
ase, PDK1 [58–60]. Therefore, one might expect that the
levels of the active form of these kinases are not always
present continuously or simultaneously under normal phys-
iological conditions. Pim-1, on the other hand, is constitu-
tively expressed at low levels but increased levels are rapidly
induced in response to variety of cytokine, hormone, antigen
or mitogen stimulation. Unlike PKC, PKA and Akt, Pim-1 is
constitutively active ([32]; Magnuson, unpublished data). It
is noteworthy that the consensus sequences that PKC, PKA,
Akt and Pim-1 preferentially phosphorylate are somewhat
different from each other but with potential overlap for
similar ‘‘target’’ sequences (Table 1). In addition, the poten-
tial impact of these kinases on controlling the phosphoryla-
tion state of p21 would also depend on activating signals and
cell type. In any case, it would be naı¨ve to assume that only
one kinase would be solely responsible for regulating the
biological function of p21. More realistically, it is probably
the combined activity of two or more of these kinases that
when expressed and/or activated, facilitate regulation of p21
function.
p21 has been shown to be involved in multiple functions.
In addition to functioning in differentiation and apoptosis,
p21 has also been shown to associate with development,
tumor suppression, senescence, and regulation of cellular
signal transduction [6–8]. Most of these cellular functions
directly depend on the interaction of p21 with a number of
associated proteins. Phosphorylation of p21 by Pim-1 regu-
lates its subcellular distribution, which in turn allows binding
to proteins which themselves have distinct subcellular loca-
tions, thus, potentially influencing numerous cellular func-
tions attributed to p21. Therefore, this might explain in part
why Pim-1 is involved in such diverse cellular functions
(differentiation, proliferation and cell survival) because one
of its substrates is also involved in multiple cellular func-
tions.
In summary, our studies demonstrate that Pim-1 interacts
with p21 (both in vitro and in vivo) and that Pim-1 can
phosphorylate p21 in vivo and regulate its subcellular dis-
tribution. Our finding of p21 as a substrate for Pim-1 kinase
provides a partial explanation for the multiple functions of
Pim-1 kinase.
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